The H3D Centre is a South African-based academic translational research unit that has had many successes and could provide a much-needed model for drug discovery and development in Africa.
References
Tegally, H. et al. Nature 592, 438–443 (2021).
Keeton, R. et al. Nature 603, 488–492 (2022).
Nordling, L. Nat. Med. 19, 803–806 (2013).
Aldridge, B. B. et al. Nat. Med. 27, 1333–1337 (2021).
Yang, T. et al. Trends Parasitol. 37, 493–507 (2021).
Le Manach, C. et al. J. Med. Chem. 64, 2291–2309 (2021).
Singh, V. & Chibale, K. Acc. Chem. Res. 54, 2361–2376 (2021).
Reader, J. et al. Nat. Commun. 12, 269 (2021).
Sinxadi, P. et al. Antimicrob. Agents Chemother. 64, e01896–19 (2020).
Brunchswig, C. et al. Antimicrob. Agents Chemother. 62, e00012–18 (2018).
Nchinda, A. T. et al. J. Med. Chem. 61, 4213–4227 (2018).
Paquet, T. et al. Sci. Transl. Med. 9, eaad9735 (2017).
Okombo, J. & Chibale, K. Acc. Chem. Res. 50, 1606–1616 (2017).
International Federation of Pharmaceutical Manufacturers and Associations. https://www.ifpma.org/wp-content/uploads/2021/09/H3D-IFPMA-Partnership.pdf (accessed April 2022).
Merck KGaA. https://www.merckgroup.com/en/news/partnership-uct-mmv-19-04-2018.html (accessed April 2022).
Johnson & Johnson. https://www.jnj.com/johnson-johnson-launches-next-satellite-center-for-global-health-discovery-at-holistic-drug-discovery-and-development-centre-university-of-cape-town-focused-on-antimicrobial-resistance-amr (accessed May 2022).
Mills, E. J. et al. BMJ 343, d7031 (2011).
Bizcommunity. https://www.bizcommunity.com/Article/196/323/192566.html (accessed April 2022).
J. C. Flowers Foundation. https://www.jcflowersfoundation.org/isdell-flowers-cross-border-malaria-initiative.html (accessed May 2022).
African Medicines Agency (AMA). https://www.nepad.org/microsite/african-medicines-agency-ama (accessed May 2022).
Sehmi, K. et al. Front. Med. Technol. 4, 810456 (2022).
Acknowledgements
The authors thank the University of Cape Town, the South African government (Department of Science and Innovation, Technology Innovation Agency, South African Medical Research Council, Department of Trade and Industry), Wolfson Foundation, Garfield Weston Foundation, Novartis, Medicines for Malaria Venture, Bill & Melinda Gates Foundation, Merck KGaA, Celgene, Royal Society, Global Challenges Research Fund, Newton Fund, Merck & Co Inc., US National Institutes of Health, Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), and Neville Isdell.
Author information
Authors and Affiliations
Contributions
K.C. designed the content and flow of the paper. S.W. and J.G.W. collected the necessary information and data. S.W., J.G.W., G.C.P. and K.C. wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Winks, S., Woodland, J.G., Pillai, G.‘. et al. Fostering drug discovery and development in Africa. Nat Med 28, 1523–1526 (2022). https://doi.org/10.1038/s41591-022-01885-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01885-1
- Springer Nature America, Inc.
This article is cited by
-
Including African data in drug discovery and development
Nature Reviews Drug Discovery (2023)
-
First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa
Nature Communications (2023)